Targeting the Hedgehog Pathway in Pediatric Medulloblastoma
Related Experiment Video
Updated: Mar 31, 2026
Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Sherri Y Huang1, Jer-Yen Yang2,3
1Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN 46202, USA. syhuangpcr@gmail.com.
Abstract:
Medulloblastoma (MB), a primitive neuroectomal tumor of the cerebellum, is the most common malignant pediatric brain tumor. The cause of MB is largely unknown, but aberrant activation of Hedgehog (Hh) pathway is responsible for ~30% of MB. Despite aggressive treatment with surgical resection, radiation and chemotherapy, 70%-80% of pediatric medulloblastoma cases can be controlled, but most treated patients suffer devastating side effects. Therefore, developing a new effective treatment strategy is urgently needed. Hh signaling controls transcription of target genes by regulating activities of the three Glioma-associated oncogene (Gli1-3) transcription factors. In this review, we will focus on current clinical treatment options of MB and discuss mechanisms of drug resistance. In addition, we will describe current known molecular pathways which crosstalk with the Hedgehog pathway both in the context of medulloblastoma and non-medulloblastoma cancer development. Finally, we will introduce post-translational modifications that modulate Gli1 activity and summarize the positive and negative regulations of the Hh/Gli1 pathway. Towards developing novel combination therapies for medulloblastoma treatment, current information on interacting pathways and direct regulation of Hh signaling should prove critical.
Insights
Medulloblastoma, a pediatric brain tumor, often involves the Hedgehog (Hh) pathway. This review explores Hh pathway regulation, drug resistance, and crosstalk with other pathways to inform new medulloblastoma combination therapies.
Area of Science:
- Neuro-oncology
- Molecular biology
- Pediatric oncology
Background:
- Medulloblastoma (MB) is the most common malignant pediatric brain tumor, originating in the cerebellum.
- Aberrant activation of the Hedgehog (Hh) pathway is implicated in approximately 30% of MB cases.
- Current treatments (surgery, radiation, chemotherapy) have significant side effects and limited long-term efficacy for many patients.
Purpose of the Study:
- To review current clinical treatment strategies for medulloblastoma.
- To discuss mechanisms of drug resistance in medulloblastoma.
- To explore molecular pathways that interact with the Hh pathway in cancer development.
Main Methods:
- Literature review focusing on medulloblastoma treatment and Hh pathway signaling.
- Analysis of molecular crosstalk between the Hh pathway and other cancer-related pathways.
- Examination of post-translational modifications affecting Gli1 activity.
Main Results:
- The Hh/Gli1 pathway is a key regulator of gene transcription in medulloblastoma.
- Understanding pathway crosstalk and regulation is crucial for developing novel therapies.
- Drug resistance mechanisms and Gli1 activity modulation are significant challenges.
Conclusions:
- Developing novel combination therapies for medulloblastoma requires a comprehensive understanding of Hh signaling and interacting pathways.
- Targeting the Hh/Gli1 pathway and its modulators offers potential for improved treatment outcomes.
- Further research into molecular interactions is critical for advancing medulloblastoma treatment strategies.
Related Concept Videos
02:33Hedgehog Signaling Pathway
02:33Hedgehog Signaling Pathway